Bausch Health Companies Inc.

BHC

CA0717341071

Pharmaceuticals

Delayed Nyse Other stock markets 16:00:02 2026-01-16 EST			5-day change	1st Jan Change
6.980 ^USD	-3.86%		-5.80%	+0.43%

01-14	Bausch Health Companies Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-14-2026 03:45 PM
01-13	Bausch Health Brief: Co Provides Filing Ahead of Participating in 44th Annual J.P. Morgan Healthcare Conference on Jan. 14, 2026	MT

Bausch + Lomb Brief: Says a potential sale is one of several options being explored to complete a full separation from Bausch Health

Published on 12/12/2024 at 07:05 am EST - Modified on 12/12/2024 at 07:13 am EST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Bausch Health Companies Inc.

01-14	Bausch Health Companies Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-14-2026 03:45 PM
01-13	Bausch Health Brief: Co Provides Filing Ahead of Participating in 44th Annual J.P. Morgan Healthcare Conference on Jan. 14, 2026	MT
01-13	Bausch Health Brief: Management Expects to Reaffirm FY25 Guidance at Higher End of Range for Itself Excluding Bausch + Lomb As Provided In October	MT
01-07	Truist Securities Adjusts Price Target on Bausch Health to $8 From $7, Maintains Hold Rating	MT
01-02	Bausch + Lomb Completes Refinancing of Outstanding Term B Loans	MT
12-29	Bausch Health Companies Inc. and 1261229 B.C. Ltd. Completes the Previously announced Offers to Exchange it?s Outstanding 4.875% Senior Secured Notes Due 2028 and 11.00% Senior Secured Notes Due 2028	CI
12-12	Bausch + Lomb Refinancing Outstanding Term B Loans	MT
12-12	Bausch + Lomb Brief: Announcing Refinancing of Outstanding Term B Loans	MT
12-09	Bausch Health Companies Inc. Announces Early Results of Senior Secured Notes Exchange Offers Announced	CI
12-02	Bausch Health Companies Inc. Presents at Evercore 8th Annual Healthcare Conference, Dec-02-2025 10:50 AM
12-01	Sector Update: Health Care Stocks Decline Late Afternoon	MT
12-01	Sector Update: Health Care Stocks Decline Monday Afternoon	MT
12-01	TSX Down 140 Points at Midday With Info Tech The Worst Performer	MT
12-01	Top Midday Stories: Nvidia's $2 Billion Stake in Synopsys; Starbucks' Nearly $39 Million Fine; Goldman Sachs to Buy Innovator Capital for $2 Billion	MT
12-01	Bausch Health's Solta Medical Unit Acquires Chinese Distribution Partner Wuhan Shibo Zhenmei Technology; Shares Rise	MT
12-01	Bausch Health's Solta Medical Unit Acquires Chinese Distribution Partner Wuhan Shibo Zhenmei Technology	MT
12-01	Bausch Health Acquires Longtime Distribution Partner, Shibo Group, to Boost China Presence	MT
12-01	Bausch Health Brief: Bausch Health's Aesthetics Business, Solta Medical, Buying Longtime Distribution Partner, Shibo Group, to Strengthen Presence in China	MT
11-24	Bausch Health announces launch of offers to exchange certain existing senior secured notes	RE
11-24	Bausch Health Launches Exchange Offer for 2028 Secured Notes	MT
25-10-30	TSX ends higher as gold rally boosts metal-mining shares	RE
25-10-30	TSX up 120 Points at Midday With Healthcare The Best Performer	MT
25-10-30	Toronto Stocks Up; Spin Master Rises as Digital Games Segment Softens Toy Sales Slump	DJ
25-10-29	Bausch Health Companies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-10-29	Bausch Health Companies Inc., Q3 2025 Earnings Call, Oct 29, 2025

Chart Bausch Health Companies Inc.

Duration

Period

BHC: Dynamic Chart

Bausch Health Companies Inc. is a global diversified pharmaceutical company. The Company develops, manufactures and markets, primarily in the therapeutic areas of gastroenterology (GI), hepatology, neurology and dermatology, and others, through Bausch + Lomb Corporation. Its Salix segment consists of sales in the United States of GI products. Its International segment consists of sales, with the exception of sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the United States and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products, and other products. Its Solta Medical segment consists of global sales of Solta Medical aesthetic medical devices. Its Diversified segment consists of sales in the United States of pharmaceutical products in the areas of neurology and certain other therapeutic classes. Its Bausch + Lomb segment consists of global sales of Bausch + Lomb Vision Care, surgical and pharmaceutical products.

Employees

20,700

Sector

Pharmaceuticals

Calendar

02-24 - Q4 2025 Earnings Release (Projected)

More about the company